<DOC>
	<DOCNO>NCT02545075</DOCNO>
	<brief_summary>The purpose study determine whether Ipilimumab extend life chinese patient Chemotherapy Naive Stage IV Melanoma Dacarbazine well examine safety patient population .</brief_summary>
	<brief_title>A Comparative Study Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab ( 3 mg/kg ) vs. Dacarbazine</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Chinese male female ≥ 18 year age Histologic diagnosis malignant melanoma Chemotherapy naive Stage IV melanoma ( AJCC 2010 ) Life expectancy ≥ 16 week Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Evidence brain metastasis brain image Primary ocular mucosal melanoma Any malignancy patient diseasefree less 5 year BRAF status determine Screening test Human Immunodeficiency Virus ( HIV ) positive hepatitis B surface antigen ( HBsAg ) positive , active Hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>